当前位置:首页>产品中心>单抗/多抗>Anti-Human CCL2/JE/MCP-1 Reference Antibody|抗人CCL2/JE/MCP-1参考抗体(靶标:人CC趋化因子配体2(单核细胞趋化蛋白1))

Anti-Human CCL2/JE/MCP-1 Reference Antibody|抗人CCL2/JE/MCP-1参考抗体(靶标:人CC趋化因子配体2(单核细胞趋化蛋白1))

  • 货号:RB9THY280016
  • 价格:面议
  • 点击:366

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG1-kappa
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度2.08 mg/ml
内毒素水平Please contact with the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标HC11, MCP-1, MCP1, Monocyte chemotactic protein 1, Monocyte chemotactic and activating factor, Small-inducible cytokine A2, SCYA2, MCAF, Monocyte secretory protein JE, C-C motif chemokine 2, Monocyte
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
表达系统Mammalian Cells
登录号P13500
背景信息Carlumab, developed by Janssen Biotech, is a recombinant human IgG1 monoclonal antibody targeting CC chemokine ligand 2 (CCL2). The recombinant protein has been developed for the treatment of cancer and prostate cancer, and has also been studied in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis, and type 2 diabetes. In the beginning, phage display technology was used to confirm the high affinity between Carlumab and CCL2, which provided a basis for future clinical trials. In 2013, Carlumab was used to treat metastatic castrated prostate cancer and solid tumors. The anti-tumor activity of Carlumab was preliminarily determined through the study of its safety, tolerance, pharmacokinetics-pharmacodynamics and anti-tumor activity. Subsequently, some studies have evaluated the safety and efficacy of Carlumab in the treatment of (IPF) with idiopathic pulmonary fibrosis, but the results are not satisfactory. Due to the limited success rate of clinical trials, carlumab was discontinued in 2012.
• MCP-1 gene (SCYA2) and schizophrenia: a case-control association study., PMID:15389752
• The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study., PMID:19923858
别名CNTO 888, 915404-94-3
种属Human
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 589
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 780
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 822
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 714
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 630
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 642
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 365
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 633
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 704
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 688
Anti-Human CD42b/GP1BA Recombinant Antibody|抗人CD42b/GP1BA重组抗体(靶标:人血小板糖蛋白Ibα链/CD42b) 818
Anti-Human JMJD1C Polyclonal Antibody|抗人JMJD1C多克隆抗体(靶标:人Jumonji结构域含蛋白1C) 647
Anti-Human ITGB6 Polyclonal Antibody|抗人ITGB6多克隆抗体(靶标:人整合素β6亚基) 844
Anti-Mouse IL33 Recombinant Antibody |抗小鼠IL33重组抗体(靶标:小鼠白细胞介素33) 578
Anti-Mouse CD1d/CD1.1 Recombinant Antibody|抗小鼠CD1d/CD1.1重组抗体(靶标:小鼠CD1d分子) 774
Anti-Mouse α5β1 (ITGA5 & ITGB1) Recombinant Antibody|抗小鼠α5β1(ITGA5和ITGB1)重组抗体(靶标:小鼠整合素α5β1复合物) 761
Anti-Mouse VEGFA Recombinant Antibody|抗小鼠VEGFA重组抗体(靶标:小鼠血管内皮生长因子A) 474
总计 33037 个记录,共 1652 页,当前第 1652 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00